Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Olga Pospelova, MD, Margarita Gurianova, MD, Nikolay Tsyba, MD PhD, Tatiana I. Ionova, Prof., Anna G. Turkina, Prof., MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141798

Published: 2020

Journal Articles

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

Francois-Xavier Mahon, MD PhD, Nelma D Clementino, MD, Mikhail Fominykh, MD, Jeffrey H. Lipton, MD PhD, Anna G. Turkina, Prof., MD, Beatriz Moiraghi, MD, Franck E Nicolini, MDPhD, Naoto Takahashi, MD PhD, Tomasz Sacha, MDPhD, Dong-Wook Kim, MD, Rafik Fellague-Chebra, MD, Ranjan Tiwari, MSc, Catherine Bouard, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136250

Published: 2020

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Tatyana Ionova, PhD Professor, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 2925.

https://doi.org/10.1182/blood-2019-122041

Published: 2019

Journal Articles

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Irina N. Shipounova, PhD, Nataliya A. Petinati, MD PhD, Nina J. Drize, PhD, Aminat A. Magomedova, MD PhD, Ekaterina A. Fastova, MD, Sergey K. Kravchenko, MD PhD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anna G. Turkina, Prof., MD, Elena N. Parovichnikova, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5014.

https://doi.org/10.1182/blood-2019-123396

Published: 2019

Journal Articles

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Blood (2019) 134 (Supplement_1): 498.

https://doi.org/10.1182/blood-2019-124430

Published: 2019

Journal Articles

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Olga V. Lazareva, PhD, Ekaterina Yu. Chelysheva, MD PhD, Anton Kulikovsky, Olga Senderova, Valentina Pepeliaeva, Sergey Meresiy, Alexander S. Luchinin, MD, Galina Milutina, Lubov Gavrilova, Ludmila Avdeeva, Dolgorzhap Dasheeva, Olga Vinogradova, MD PhD, Sergei M. Kulikov, PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 5902.

https://doi.org/10.1182/blood-2019-131430

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Ekaterina Chelysheva, MD PhD, Jane Apperley, MB ChB MD, Elisabetta Abruzzese, Dong-Wook Kim, MD PhD, Konstantin Kotlyarchuk, Oleg Shukhov, MD PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2018-99-115984

Published: 2018

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up

Ekaterina Chelysheva, MD PhD, Elisabetta Abruzzese, Delphine Rea, MD, Dong-Wook Kim, MD PhD, Khamida Kazakbaeva, MD, Sukhrob Saliev, Konstantin Kotlyarchuk, Evgenia Polushkina, Roman Shmakov, MD PhD, Julia Chabaeva, Sergei M. Kulikov, PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2018-99-115983

Published: 2018

Journal Articles

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Anna Petrova, MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G Turkina, Prof., MD, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Zinkovskaya, Tatiana Ionova, DSc

Blood (2018) 132 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2018-99-113360

Published: 2018

Journal Articles

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

Sergei M. Kulikov, PhD, Anna G Turkina, Prof., MD, Anton Kulikovsky, Olga Lazareva, PhD, Sergey Kutsev, Prof., MD, PhD, Elza Lomaia, MD, Andrey Zaritskey, MD PhD, Anatoly Golenkov, MDProf, Tatiana Pospelova, MD PhD, Satokhin Yuri, MD PhD, Tatiana Konstantinova, MD PhD, Elena N. Parovichnikova, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2018) 132 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2018-99-114700

Published: 2018

Journal Articles

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Oleg Shukhov, MD PhD, Ekaterina Chelysheva, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Galina Gusarova, MD PhD, Eduard Gemdzhian, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2018-99-116321

Published: 2018

Journal Articles

Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra -Positive Neoplasm

Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2018-99-116262

Published: 2018

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Dong-Wook Kim, MD PhD, Yeow Tee Goh, MBBS,MD, Iryna Dyagil, MDPhD, Katia B Pagnano, MD, Árpád Bátai, MD, Anna G Turkina, Prof., MD, Jean M. Aguiar, RN, Eric Leip, PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 900.

https://doi.org/10.1182/blood.V130.Suppl_1.900.900

Published: 2017

Journal Articles

Dynamics of Gene Expression of Surface Receptors of Apoptosis in Primary Patients with B-CLL during Induction Treatment

Sergei Zakharov, Anatoly Golenkov, MDProf, Vsevolod A. Misyurin, PhD, Elena Kataeva, MD, Andrey Misyurin, PhD, Tatiana Mitina, MD, Baryshnikova Maria, PhD, Elena Trifonova, MD PhD, Yulia Chernykh, Ludmila Vysotskaya, PhD, Elena Klinushkina, Anna G Turkina, Prof., MD, Kirill Belousov

Blood (2017) 130 (Supplement 1): 4970.

https://doi.org/10.1182/blood.V130.Suppl_1.4970.4970

Published: 2017

Journal Articles

Alterations in Mesenchymal Stromal Precursor Cells in Patients with Chronic Myeloid Leukemia at the Onset of the Disease and During Treatment By Tyrosine Kinase Inhibitors

Nataliya Petinati, PhD MD, Irina Shipounova, PhD, Alexey Bigildeev, PhD, Natalia Sats, PhD, Tamara Sorokina, MD, Ekaterina Chelysheva, MDPhD, Oleg Shukhov, MDPhD, Anna Petrova, MD, Anna G Turkina, Prof., MD, Nina Drize, PhD

Blood (2017) 130 (Supplement 1): 5242.

https://doi.org/10.1182/blood.V130.Suppl_1.5242.5242

Published: 2017

Journal Articles

The Analysis of 12-Year Overall Survival in Non-Selected Patients with Chronic Myeloid Leukemia with Tyrosinekinase Inhibitors Therapy in Routine Practice

Lyudmila Vysotskaya, Tatiana Mitina, Elena Trifonova, MD PhD, Yulia Chernykh, Sergei Zakharov, Kirill Belousov, Elena Klinushkina, Elena Kataeva, MD, Anna G Turkina, Prof., MD, Anatoly Golenkov, MDProf

Blood (2017) 130 (Supplement 1): 5261.

https://doi.org/10.1182/blood.V130.Suppl_1.5261.5261

Published: 2017

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra -Positive Neoplasm

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Dynamics of Gene Expression of Surface Receptors of Apoptosis in Primary Patients with B-CLL during Induction Treatment

Alterations in Mesenchymal Stromal Precursor Cells in Patients with Chronic Myeloid Leukemia at the Onset of the Disease and During Treatment By Tyrosine Kinase Inhibitors

The Analysis of 12-Year Overall Survival in Non-Selected Patients with Chronic Myeloid Leukemia with Tyrosinekinase Inhibitors Therapy in Routine Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only